Drug Profile
BLO 020
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bausch Health Companies
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ocular inflammation
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Ocular-inflammation in USA
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 13 Jan 2016 Clinical trials in Ocular inflammation in USA (unspecified route)